Decheng Capital Global Life Sciences Fund IV, L.P. 13D/13G Filings for

Decheng Capital Global Life Sciences Fund IV, L.P. 13D and 13G filings for :

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2025-02-24
4:16 pm
Purchase
2025-02-1413GAardvark Therapeutics, Inc. Common Stock
AARD
Decheng Capital Global Life Sciences Fund IV, L.P.3,917,299
18.300%
3,917,299increase
(New Position)
Filing